Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company
2024年9月27日 - 9:00PM
ビジネスワイヤ(英語)
Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage
biotechnology company developing next-generation therapeutics for
the treatment of cardiovascular diseases, today announced that it
has been named as one of the Endpoints 11 most promising private
biotechnology companies of 2024. Cardurion has been chosen by the
Endpoints News editorial team because of the company’s strengths in
science, leadership, investors and strategy to develop the next
generation of therapeutics for the treatment of patients with
cardiovascular diseases.
“On behalf of the entire Cardurion team, we are honored to be
recognized as an Endpoints 11 company,” said Peter Lawrence, Chief
Executive Officer of Cardurion. “This award serves as a testament
to the quality of work, dedication and focus of our team, and the
progress we have made with our two first-in-class clinical programs
for the treatment of patients with cardiovascular disease. We are
excited to continue our momentum towards developing medicines to
help the millions of people who suffer from or are at risk of
cardiovascular diseases, which remain the leading cause of death in
the US and globally."
The 2024 Endpoints 11 winners were announced at an awards gala
held in Boston on Thursday, September 26, 2024.
Cardurion is developing next-generation therapeutics for the
treatment of cardiovascular diseases, including:
- PDE9 inhibitor, CRD‑750, is being evaluated in two Phase
2 clinical trials in 640 patients with both types of chronic heart
failure, HFrEF and HFpEF.
- CaMKII inhibitor, CRD-4730, is being evaluated in a
Phase 2 clinical trial for the treatment of patients with
catecholaminergic polymorphic ventricular tachycardia (CPVT), a
rare genetic arrhythmic disease.
- Cardurion is also planning to grow its pipeline by expanding
its CaMKII clinical program to include additional cardiovascular
indications and advancing new drug candidates targeting other unmet
patient needs in the cardiovascular disease area.
About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a clinical-stage biotechnology
company focused on the discovery and development of novel,
next-generation therapeutics for the treatment of patients with
cardiovascular diseases. Cardurion was founded by
physician-scientists with world-class expertise in cardiovascular
signaling pathways, and a shared passion to find and develop a
pipeline of novel treatment options to improve the lives of
patients. Cardurion has two groundbreaking clinical programs in
development, a first-in-class phosphodiesterase-9 (PDE9) inhibitor
for both types of chronic heart failure and the first-ever
clinical-stage Calcium/Calmodulin-dependent Protein Kinase II
(CaMKII) inhibitor for rare and common cardiovascular diseases.
Cardurion Pharmaceuticals is headquartered in Burlington,
Massachusetts, with discovery sciences and research facilities in
Shonan, Japan. For more information, please visit the company’s
website at https://cardurion.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927193940/en/
Media: Kathryn Morris The Yates Network LLC 914-204-6412
kathryn@theyatesnetwork.com